Fatemeh Ebrahimi1,2, Amirhossein Sahebkar3,4,5, Naheed Aryaeian2, Naseh Pahlavani6, Soudabeh Fallah7, Nariman Moradi8, Davoud Abbasi9, Agha Fatemeh Hosseini10. 1. Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. 3. Halal Research Center of IRI, FDA, Tehran, Iran. 4. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran. 7. Department of Clinical Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran. 8. Department of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. 9. Department of Internal Medicine, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran. 10. Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: Type 2 diabetes (T2D) is accompanied by elevated inflammation, oxidative stress, hyperlipidemia and hyperglycemia which all contribute to cardiovascular disease pathogenesis. Saffron as a complementary medicine and source of antioxidants could play a role in alleviating diabetes and its complications. The aim of this study was to determine the effects of saffron supplementation as an adjunct therapy in T2D. PATIENTS AND METHODS: This randomized controlled trial included 80 T2D patients with a mean age of 54.1 years. Participants were randomly assigned into two groups to take either saffron tablets (100 mg/day; n=40) or placebo (n=40) for 12 weeks. Fasting blood samples were obtained at the beginning and after the intervention period to quantify glycemic factors, lipid profile, and biomarkers of inflammation and oxidative stress. Anthropometric indices and dietary intakes were also measured at baseline and at study end. RESULTS: Compared with placebo, saffron supplementation resulted in significant decreases in waist circumference (p<0.001) and malondialdehyde (MDA) (p=0.001). There was no statistically significant difference in other indices, including anthropometric parameters, serum insulin, fasting blood glucose, HbA1c, insulin sensitivity indices, lipid profile, high-sensitivity C-reactive protein, total antioxidant capacity, and tumor necrosis factor-α between the study groups (p>0.05). CONCLUSION: Overall, 12 weeks of saffron supplementation in diabetic patients had beneficial effects on waist circumference and serum MDA levels. However, saffron did not influence other evaluated cardio metabolic risk markers in diabetic patients.
BACKGROUND: Type 2 diabetes (T2D) is accompanied by elevated inflammation, oxidative stress, hyperlipidemia and hyperglycemia which all contribute to cardiovascular disease pathogenesis. Saffron as a complementary medicine and source of antioxidants could play a role in alleviating diabetes and its complications. The aim of this study was to determine the effects of saffron supplementation as an adjunct therapy in T2D. PATIENTS AND METHODS: This randomized controlled trial included 80 T2D patients with a mean age of 54.1 years. Participants were randomly assigned into two groups to take either saffron tablets (100 mg/day; n=40) or placebo (n=40) for 12 weeks. Fasting blood samples were obtained at the beginning and after the intervention period to quantify glycemic factors, lipid profile, and biomarkers of inflammation and oxidative stress. Anthropometric indices and dietary intakes were also measured at baseline and at study end. RESULTS: Compared with placebo, saffron supplementation resulted in significant decreases in waist circumference (p<0.001) and malondialdehyde (MDA) (p=0.001). There was no statistically significant difference in other indices, including anthropometric parameters, serum insulin, fasting blood glucose, HbA1c, insulin sensitivity indices, lipid profile, high-sensitivity C-reactive protein, total antioxidant capacity, and tumor necrosis factor-α between the study groups (p>0.05). CONCLUSION: Overall, 12 weeks of saffron supplementation in diabetic patients had beneficial effects on waist circumference and serum MDA levels. However, saffron did not influence other evaluated cardio metabolic risk markers in diabetic patients.
Authors: Charlotte Kragelund; Ole Snorgaard; Lars Køber; Bruno Bengtsson; Michael Ottesen; Søren Højberg; Claus Olesen; Jens-Jørgen Kjaergaard; Jan Carlsen; Christian Torp-Petersen Journal: Eur Heart J Date: 2004-11 Impact factor: 29.983
Authors: Kaushik Chattopadhyay; Haiquan Wang; Jaspreet Kaur; Gamze Nalbant; Abdullah Almaqhawi; Burak Kundakci; Jeemon Panniyammakal; Michael Heinrich; Sarah Anne Lewis; Sheila Margaret Greenfield; Nikhil Tandon; Tuhin Kanti Biswas; Sanjay Kinra; Jo Leonardi-Bee Journal: Front Pharmacol Date: 2022-06-08 Impact factor: 5.988
Authors: Dana Hasan Alkhatib; Abdul Jaleel; Maryam Naveed Muhammad Tariq; Jack Feehan; Vasso Apostolopoulos; Leila Cheikh Ismail; Lily Stojanovska; Ayesha S Al Dhaheri Journal: Nutrients Date: 2021-12-30 Impact factor: 5.717